Dual receptor agonist for glucose-dependent insulinotropic polypeptide (GIP) and GLP-1Superior efficacy in T2DM and obesity when compared with semaglutide22Half-life = ∼5 d. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.